277 related articles for article (PubMed ID: 32425919)
1. Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway.
Xu X; Lv J; Guo F; Li J; Jia Y; Jiang D; Wang N; Zhang C; Kong L; Liu Y; Zhang Y; Lv J; Li Z
Front Microbiol; 2020; 11():814. PubMed ID: 32425919
[TBL] [Abstract][Full Text] [Related]
2. Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Wang T; Wu L; Wang S; Shi X; Liu H; Deng W
Chin J Nat Med; 2023 May; 21(5):333-345. PubMed ID: 37245872
[TBL] [Abstract][Full Text] [Related]
3. Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment.
Lv J; Jia Y; Li J; Kuai W; Li Y; Guo F; Xu X; Zhao Z; Lv J; Li Z
Cell Death Dis; 2019 May; 10(6):415. PubMed ID: 31138779
[TBL] [Abstract][Full Text] [Related]
4. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
5. Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers.
Li J; Guo Y; Liu J; Guo F; Du L; Yang Y; Li X; Ma Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597851
[TBL] [Abstract][Full Text] [Related]
6. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiota distinct between colorectal cancers with deficient and proficient mismatch repair: A study of 230 CRC patients.
Jin M; Wu J; Shi L; Zhou B; Shang F; Chang X; Dong X; Deng S; Liu L; Cai K; Nie X; Zhang T; Fan J; Liu H
Front Microbiol; 2022; 13():993285. PubMed ID: 36312959
[TBL] [Abstract][Full Text] [Related]
8. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors.
Cai L; Chen A; Tang D
Immunology; 2024 Mar; ():. PubMed ID: 38517066
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report.
Cheng X; Li X; Yang X; Fang S; Wang Z; Liu T; Zheng M; Zhai M; Yang Z; Shen T
Cureus; 2023 Jul; 15(7):e42347. PubMed ID: 37621810
[TBL] [Abstract][Full Text] [Related]
10. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
11. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
12. The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer.
Sillo TO; Beggs AD; Middleton G; Akingboye A
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982838
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
[TBL] [Abstract][Full Text] [Related]
14. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
15. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
16. Gegen Qinlian decoction enhances immunity and protects intestinal barrier function in colorectal cancer patients
Li Y; Li ZX; Xie CY; Fan J; Lv J; Xu XJ; Lv J; Kuai WT; Jia YT
World J Gastroenterol; 2020 Dec; 26(48):7633-7651. PubMed ID: 33505141
[TBL] [Abstract][Full Text] [Related]
17. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers.
Hale VL; Jeraldo P; Chen J; Mundy M; Yao J; Priya S; Keeney G; Lyke K; Ridlon J; White BA; French AJ; Thibodeau SN; Diener C; Resendis-Antonio O; Gransee J; Dutta T; Petterson XM; Sung J; Blekhman R; Boardman L; Larson D; Nelson H; Chia N
Genome Med; 2018 Oct; 10(1):78. PubMed ID: 30376889
[TBL] [Abstract][Full Text] [Related]
18. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer.
Baraibar I; Mirallas O; Saoudi N; Ros J; Salvà F; Tabernero J; Élez E
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944931
[TBL] [Abstract][Full Text] [Related]
19. Application of immune checkpoint inhibitors in colorectal cancer.
Wang L; Huang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
[TBL] [Abstract][Full Text] [Related]
20. Identification of the molecular characteristics associated with microsatellite status of colorectal cancer patients for the clinical application of immunotherapy.
Fu J; Jin X; Chen W; Chen Z; Wu P; Xiao W; Liu Y; Deng S
Front Pharmacol; 2023; 14():1083449. PubMed ID: 36814498
[No Abstract] [Full Text] [Related]
[Next] [New Search]